Core Viewpoint - Lingrui Pharmaceutical's subsidiary, Yingu Pharmaceutical, has received approval from the National Medical Products Administration for the new indication of phenylpropanolamine nasal spray to treat cold symptoms, enhancing its market position in the nasal medication sector [1] Group 1: Product Development - The phenylpropanolamine nasal spray is now approved for alleviating symptoms such as runny nose, nasal congestion, nasal itching, and sneezing caused by colds [1] - Previously, the product was approved for treating symptoms related to allergic rhinitis and is included in the "Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis" [1] - This nasal spray is the only approved anticholinergic nasal medication for allergic rhinitis in China, with a market size of approximately 5.4 billion yuan [1] Group 2: Market Impact - The new indication for cold symptoms positions the product as the first M receptor antagonist nasal spray for post-cold nasal symptoms in China, which is expected to enhance its product strength [1] - Cumulative research and development investment for this product has reached approximately 35.97 million yuan [1]

Summary of Key Points Core Viewpoint - Lingrui Pharmaceutical (600285) has experienced a decline in stock price, closing at 23.64 yuan as of June 13, 2025, down 1.79% from the previous week [1] Company Announcements - Lingrui Pharmaceutical announced a cash dividend of 0.90 yuan per share, with the record date set for June 19, 2025. The ex-dividend date and payment date are both June 20, 2025 [1] - The total cash dividend distribution amounts to 510,403,937.40 yuan, based on a total share capital of 567,115,486 shares [1] - Different types of shareholders will receive varying actual cash dividends: - Individual shareholders and securities investment funds (holding period over 1 year) will receive 0.90 yuan per share - QFII shareholders will receive 0.81 yuan per share (after a 10% corporate income tax deduction) - Hong Kong Stock Exchange investors will also receive 0.81 yuan per share (after a 10% tax deduction) - Other institutional investors and corporate shareholders will receive a pre-tax cash dividend of 0.90 yuan per share [1]

Core Viewpoints - The Chinese medicine industry is expected to see a performance turning point, with significant improvements in revenue and profit growth anticipated in Q2 2025 compared to Q1 2025, and continued growth in H2 2025 [3][7] - The industry exhibits characteristics similar to the banking sector, including high cash reserves, substantial dividends, and low profit volatility, with minimal impact from overseas situations [3][7] Key Indicators Tracking - Influenza data has stabilized, reducing revenue growth pressure on companies [11] - The price index of Chinese medicinal materials has declined, which is expected to alleviate gross margin pressure [13] - Institutional holdings are low, with the proportion of fund holdings in the Chinese medicine sector dropping to 0.46% as of Q1 2025, indicating potential for increased investment interest under favorable tariff policies in the U.S. [18] - The sector's valuation is slightly above the average level since 2021, with a TTM price-to-earnings ratio of 27.78x as of June 12, 2025 [21] Investment Recommendations - Companies with stable and rapid profit growth and new consumption logic include Dong'e Ejiao and Lingrui Pharmaceutical, with a focus on Mayinglong [30] - High-barrier, large-cap state-owned enterprises with light institutional positions include Tianshili, Yunnan Baiyao, Tongrentang, and Pianzaihuang [30][6] Mid-Year Performance Outlook - The report provides a forecast for the first half of 2025, indicating expected year-on-year growth rates for various companies, with Dong'e Ejiao projected to grow by approximately 20% in Q2 2025 [34]

证券代码：600285 证券简称：羚锐制药 公告编号：2025-027 重要内容提示： 每股分配比例 A 股每股现金红利0.90元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 否 河南羚锐制药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本567,115,486股为基数，每股派发现金红利0.90 元（含税），共计派发现金红利510,403,937.40元。 者重大遗漏，并对其内容的真 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Group 1 - The company is a leading player in the traditional Chinese medicine patch industry, with a stable growth in performance, achieving a revenue of 3.501 billion yuan in 2024 (+5.72%) and a net profit of 723 million yuan (+27.19%) [1] - In Q1 2025, the company reported a revenue of 1.021 billion yuan (+12.29%) and a net profit of 217 million yuan (+13.89%) [1] - The core products showed steady growth, with revenues from patches, tablets, capsules, ointments, and other categories reaching 2.115 billion, 356 million, 752 million, 128 million, and 148 million yuan respectively, with year-on-year growth rates of +3.35%, +35.60%, +5.66%, -7.09%, and -1.20% [1] Group 2 - The company has a strong market presence in external traditional Chinese medicine patches, with annual sales of the Tongluo Pain Relief Patch exceeding 1 billion yuan and the "Two Tigers" series products selling over 1 billion patches annually [1] - The company’s R&D expense ratio for 2024 was 3.76% (+0.45 percentage points), focusing on major diseases and products in orthopedics, respiratory, skin, and digestive systems [2] - The company signed a letter of intent for acquisition with Yingu Holdings Group in December 2024, aiming to acquire a controlling stake in Yingu Pharmaceutical, which aligns with its strategic planning and enhances its product matrix with high-tech nasal sprays and inhalants [2] Group 3 - The company expects net profits for 2025-2027 to be 831 million, 932 million, and 1.056 billion yuan, representing year-on-year growth of +15.0%, +12.2%, and +13.4% respectively [2] - The company maintains a leading brand advantage in the traditional Chinese medicine patch sector, with a solid market share for multiple products, and continues to enhance its product matrix through R&D and acquisitions [2]

证券代码：600285 证券简称：羚锐制药 公告编号：2025-026 号 河南羚锐制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 06 月 03 日(星期二)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2025 年 05 月 26 日（星期一）至 05 月 30 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （600285@lingrui.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 （一）会议召开时间：2025 年 06 月 03 日下午 15:00-16:00 （二）会议召开地点："上证路演中心"（http://roadshow.ss ...

重要内容提示： 本次会议是否有否决议案：无 证券代码：600285 证券简称：羚锐制药 公告编号：2025-025 河南羚锐制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 20 日 (二)股东大会召开的地点：河南省新县将军路 666 号羚锐制药会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 489 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 205,137,057 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 36.1720 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，采用现场投票和网络投票相结合的方式召 开，现场会议由董事长熊伟先生主持。会议的召集、召开及表决方式符合《公司 法》 ...

二〇二五年五月 地址：湖北省武汉市武昌和平大道三角路恒大首府 55 楼 电话：027-87123860 传真：027-87819960 北京金台(武汉)律师事务所 关于河南羚锐制药股份有限公司 2024 年年度股东大会的法律意见书 致：河南羚锐制药股份有限公司 北京金台（武汉）律师事务所（以下简称"本所"）接受河南羚锐制药股份 有限公司（以下简称"公司"）委托，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司股东大会规则》（以下简称《股东大会规则》） 等我国现行法律、法规和规范性文件及《河南羚锐制药股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，就公司 2024 年年度股东大会（以下简 称"本次股东大会"）出具本法律意见书。 北京金台（武汉）律师事务所 关于河南羚锐制药股份有限公司 2024 年年度股东大会 之法律意见书 为出具本法律意见书，本所律师根据法律的要求，按照律师行业公认的业务 标准、道德规范和勤勉尽责的精神，查验了公司提供的有关公司召开本次股东大 会的文件，包括但不限于 2025 年 4 月 24 日召开的第九届董事会第十五次会议决 议、第九届监事会第十三次会议决议及 ...

为进一步加强与投资者的互动交流，河南羚锐制药股份有限公司定于2025 年5月22日（周四）15:25-16:55参加在全景网举办的河南辖区上市公司2025年投 资者网上集体接待日活动，本次活动将采用网络远程的方式举行，投资者可登录 "全景•路演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长熊伟先生、董事兼董事 会秘书冯国鑫先生、财务总监余鹏先生（如有特殊情况，参会人员将可能进行调 整）。届时公司管理层将通过网络在线问答互动的形式，与投资者就其关注的问 题进行交流。欢迎广大投资者积极参与。 特此公告。 关于参加河南辖区上市公司2025年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600285 证券简称：羚锐制药 公告编号：2025－024号 河南羚锐制药股份有限公司 河南羚锐制药股份有限公司董事会 二〇二五年五月十七日 ...